このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Phase I Trial of a Single Administration of aKLmRNA-Mediated Protein Replacement Therapy (AKL003)

2026年11月9日 更新者:Klothea Bio Inc

An Open-Label, Single-Arm Phase I Trial to Evaluate the Safety, Tolerability, and Serum Alpha-Klotho Protein Expression Following a Single Administration of Alpha Klotho mRNA (aKLmRNA), AKL003

This is an open-label, single-arm, single-site Phase I trial in a total of 20 healthy participants at GARM Próspera, Roatán, Honduras. Each participant receives one intravenous administration of 0.5 mg AKL003 on Day 0.

Screening is followed by one treatment visit at GARM Próspera covering Day -1 to Day 2. Scheduled follow-up comprises Day 7 and the actual remote Final Visit (nominal Day 28 ±7 days), following local assessments under Investigator oversight.

Safety is assessed through adverse events, clinical examinations, vital signs, ECG and laboratory testing. Six months of passive safety follow-up after the individual Final Visit or Early Termination Visit.

PsyTool, QoL, Oura and DNA methylation assessments are retained. Exploratory changes do not establish clinical efficacy without a concurrent control group.

調査の概要

状態

募集

介入・治療

詳細な説明

This is an open-label, single-arm, single-site Phase I trial evaluating safety, tolerability and serum alpha-Klotho protein expression after a single intravenous administration of AKL003, a proprietary alpha-Klotho mRNA formulated in lipid nanoparticles. Twenty participants in total will receive AKL003 at GARM Próspera, Roatán, Honduras.

Each participant will receive one 0.5 mg intravenous administration on Day 0. Screening and later laboratory follow-up may be conducted through designated providers in the USA under the responsible Investigator's oversight. One treatment visit at GARM Próspera, Roatán, Honduras is required, covering Day -1 through Day 2. Scheduled follow-up comprises Day 7 and the actual remote Final Visit (nominal Day 28 ±7 days), following local laboratory and physical assessments. All participants follow the protocol-defined eligibility criteria, dose, pre- and post-treatment dexamethasone regimen, assessment schedule and safety procedures.

Systemic reactogenicity events, including fever, headache, myalgia, fatigue, nausea/vomiting, diarrhea and increased heart rate, will be assessed as adverse events. Severity will be graded ; CRS will be graded according to ASTCT criteria where applicable.

All participants will be informed about potential clinical activity and reactogenicity, which may be influenced by increased aKL serum levels or the lipid nanoparticle formulation. Participants will be instructed to contact the trial site to schedule an on-site visit in case of any unexpected adverse event (unscheduled visit,). All such occurrences will be documented as part of the drug candidate's safety evaluation.

Participants will use an electronic diary for daily symptoms through Day 7 and report new or worsening symptoms promptly throughout follow-up. Quality-of-life questionnaires will be completed at baseline and weekly during follow-up, including the actual Final Visit. Oura-derived measures will be collected from screening through the actual Final Visit. PsyTool assessments and other exploratory measures will be collected at different timepoints.

After the individual Final Visit or Early Termination Visit, safety information received during six months of passive follow-up will be assessed. This period adds no scheduled study visits, routine diary entries, questionnaires or biomarker samples. The Investigator may arrange additional care or assessments when clinically indicated.

The primary purpose is safety and tolerability assessment. Without a concurrent control group, exploratory changes may reflect natural variability, practice effects, concomitant factors or expectation effects. They will be interpreted as hypothesis-generating observations.

研究の種類

介入

入学 (推定)

20

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

35年~85年 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Subjects will only be included in the trial if they meet all following criteria:

  1. Written informed consent (ICF) signed and dated by the patient
  2. Ability and willingness to co-operate with the investigator and to comply with the requirements of the entire study.
  3. Healthy subjects, 35 to 85 years of age
  4. Sexually active females of childbearing potential and male partners of sexually active females of childbearing potential must use medically accepted form of contraception or be surgically sterile (hysterectomy or bilateral oophorectomy).
  5. Women of childbearing potential and men with female partners of childbearing potential must use an effective method of birth control during the course of the trial and for at least 90 days after the last dose in a manner such that risk of failure is minimized. Male participants should refrain from donating sperm during the intervention period and for at least 90 days after the last dose of study intervention (see additional considerations in section 5.3)
  6. Females of childbearing potential must have a negative pregnancy test at the time of enrollment (serum hCG test)

Exclusion Criteria:

Subjects will be excluded from the trial if they present one or more of the following conditions:

  1. Known of suspected allergy to IMP or related procedure
  2. Known or suspected allergy, or history of anaphylaxis, to vaccines or their excipients, if considered relevant by the Investigator
  3. Contraindications for the use of emergency treatments
  4. Clinically relevant findings at screening, e.g., active diseases of any kind particularly infections
  5. History of chronic alcohol or drug abuse/ dependence within the past 5 yearsUse of any prescription or over-the-counter medication within 7 days prior to first dosing or planned use during the study period, with the exception of medications considered medically necessary and administered at a stable dose and regimen. Stable medication is defined as medication for which no initiation, discontinuation, or dose adjustment has occurred for at least 3 monthsprior to first dosing and for which no change is anticipated during the study period. Occasional use of paracetamol (acetaminophen) and/or ibuprofen is permitted at the discretion of the investigator.
  6. Employee at the study site, spouse/partner or relative of any study staff (e.g., investigator, sub investigators, or study nurse) or employee of the Sponsor
  7. Known or suspected pregnancy, planned pregnancy of lactation
  8. Clinically significant unstable psychiatric illness in the past 6 months
  9. Presence of autoimmune disease, autoinflammatory syndrome, or immunological deficiency syndrome (including human immunodeficiency virus (HIV) infection)
  10. Relevant cardiovascular, hepatic, gastroenterological, respiratory, endocrinological, hematologic disease, or any other condition that, in the Investigator's opinion, could interfere with the analyses of safety and efficacy in this study, unless patient has been on stable doses of medication for any of these concurrent illnesses for at least 3 months prior to study entry
  11. Presence of end stage kidney failure (on dialysis)
  12. Current or anticipated use of immunosuppressive drugs such as, but not limited to, azathioprine, cyclosporine, methotrexate, tacrolimus, or mycophenylate within 2 months or any myelosuppressive or cytotoxic chemotherapies within the 12 months prior to the screening visit. Use of systemic corticosteroids equivalent to ≥20mg/week prednisone within the past 4 weeks before screening and during the course of the study (intranasal or inhaled steroids for allergies/asthma is allowed)
  13. History within the last 2 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal prostate-specific antigen posttreatment; or has a life expectancy of <2 years.
  14. Patients with long covid-19 showing long-term neurological sequelae within the past 12 months at the time of screening
  15. Has had a history within the last 5 years of a serious infectious disease affecting the brain, liver, lung and/or kidneys.
  16. Refractory epilepsy (has had seizures within the past 2 years)
  17. Hypothyroidism or vitamin B12 deficiency (patients with corrected hypothyroidism or vitamin B12 deficiency are eligible for the study provided that treatment has been stable for 3 months before study entry)
  18. Patient has hemochromatosis
  19. 19. Pre-existing anti-PEG antibodies at screening: anti-PEG IgM ≥5,000 U/mL or anti-PEG IgG ≥1,000 U/mL, as measured by the designated screening assay.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:aKLmRNA (AKL003)

Each subject will be treated every 4 weeks for a total of 2 times with aKLmRNA (AKL003)

Each subject will be treated every 4 weeks for a total of 2 times with aKLmRNA via i.v.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Overall incidence and severity of unsolicited AEs by treatment group
時間枠:From first dose through end of study (Day 28)

• To characterize the overall safety and tolerability of multiple administrations of the Investigational Medicinal product (IMP), aKLmRNA (AKL003), in healthy volunteers

From first dose through end of study (Day 28)
• Overall incidence and severity of solicited reactogenicity events by treatment group
時間枠:From first dose through end of study (Day 28)

• To characterize the overall safety and tolerability of multiple administrations of the Investigational Medicinal product (IMP), aKLmRNA (AKL003), in healthy volunteers

From first dose through end of study (Day 28)

二次結果の測定

結果測定
メジャーの説明
時間枠
• Increase in serum aKL levels over the mean of the baseline values until end of study
時間枠:Baseline through Day 28

• To characterize the serum levels of aKL protein as a function of the dose applied and time post administration.

Baseline through Day 28
• aKL serum level by treatment group
時間枠:Baseline through Day 28

• To characterize the serum levels of aKL protein as a function of the dose applied and time post administration.

Baseline through Day 28

その他の成果指標

結果測定
メジャーの説明
時間枠
• Change from baseline to day 60 in episodic memory performance measrued by Face-Name Associative Memory Exam
時間枠:Baseline through Day 28

• To characterize the clinical activity after multiple administrations of aKLmRNA AKL003

Baseline through Day 28
• Change from baseline to day 60 in attention and inhibitory control measured Flanker Test
時間枠:Baseline through Day 28

• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, including cognitive function

Baseline through Day 28
• Change from baseline to day 60 in working memory performance measured by NIH Toolbox List Sorting Working Memory Test
時間枠:Baseline through Day 28

• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, including cognitive function

Baseline through Day 28
• Change from baseline to day 60 in processing speed assessed by Oral Symbol Digit Test
時間枠:Baseline through Day 28

• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, including cognitive function

Baseline through Day 28
• Change from baseline to day 60 in reaction time using digital repeated measures
時間枠:Baseline through Day 28

• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, including cognitive function,

Baseline through Day 28
• Change from baseline in selected standardized neuropsychological assessments aligned with established cognitive testing platforms (CANTAB-based measures)
時間枠:Baseline through Day 28

• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, including cognitive function,

Baseline through Day 28
• Change from baseline to day 60 in grip strength measured by a hand dynamometer
時間枠:Baseline through Day 28

• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, physical (muscle) function

Baseline through Day 28
• Change from baseline to day 60 in functional exercise capacity assessed by6 -minute walk test
時間枠:Baseline through Day 28

• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, physical (muscle) function

Baseline through Day 28
• Change from baseline to day 60 in lower body functional performance assessed by chair-rise or comparable assessment
時間枠:Baseline through Day 28

• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, physical (muscle) function

Baseline through Day 28
• Change from baseline to day 60 in NAD+ levels measured in serum
時間枠:Baseline through Day 28

• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, i immune/inflammatory function

Baseline through Day 28
Change from baseline in telomere length (T/S ratio) in peripheral blood mononuclear cells (PBMCs), as measured by quantitative PCR (qPCR), at Day 60
時間枠:Baseline through Day 28
Baseline through Day 28

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Douglas A Tucker, MD、GARM

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年10月15日

一次修了 (推定)

2027年4月30日

研究の完了 (推定)

2027年5月30日

試験登録日

最初に提出

2026年4月5日

QC基準を満たした最初の提出物

2026年4月15日

最初の投稿 (実際)

2026年4月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • AKL003

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する